Dr. Grivas on the Future of the TROPHY U-01 Regimen in Urothelial Cancer

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington (UW) School of Medicine, clinical director, Genitourinary Cancers Program, UW Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer ResearchCenter, discusses the future of the phase 2 TROPHY U-01 trial (NCT03547973) regimen in metastatic urothelial cancer.

Cohort 3 of the TROPHY-U-01 trial evaluated sacituzumab govitecan-hziy (Trodelvy) in combination with pembrolizumab (Keytruda) in patients with metastatic urothelial cancer who have progressed following a platinum-based chemotherapy in the front-line setting.

The objective response rates seen were promising when considering the number of patients who presented with multiple negative prognostic and risk factors, Grivas says. Moreover, response rates seen with prior chemotherapy were low, and many patients experienced rapid disease progression, Grivas adds. Taking these baseline characteristics into consideration, the 34% response rate and 63% of reduction in tumor size seen in patients was considerable, Grivas says.

Overall, this combination is active and merits further investigation in the platinum-refractory and first-line settings, Grivas continues. Although the data are not practice changing yet, the findings support further investigation of this combination in different lines of therapy, Grivas concludes.